Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auranofin and Sirolimus in Recurrent Serous Ovarian Cancer
NCT03456700Phase 2
Key facts
- Status
- Terminated
- Start
- Mar 2018
- Primary completion
- Jul 2019
- Countries
- 1
- Sponsor
- Mayo Clinic
- Modality
- Small Molecules
- Conditions
- ovarian cancer
01
Overview
Phase 2, open-label, single-arm trial of auranofin and sirolimus in ovarian cancer, sponsored by Mayo Clinic. Primary endpoint: Overall Tumor Response Rate. Started Mar 2018; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Treatment (auranofin, sirolimus)
Auranofin and Sirolimus combination therapy
03
Who it enrols
Patients with recurrent serous ovarian cancer, ECOG 0-1, measurable disease, and adequate organ function. Excludes platinum-sensitive disease, leptomeningeal disease, and uncontrolled brain metastases.
04
Endpoints
Primary
Overall Tumor Response Rate
Secondary
Overall Tumor Response Rate in PKCiota Overexpression Subset
Progression-Free Survival
Overall Survival
Incidence of Grade 3 or Worse Adverse Events
Beyond the preview
Go deeper on NCT03456700.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456700.